A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Relapsed/Refractory Small Cell Lung Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 240 (planned)
- Started
- Feb 3, 2026
- Main results expected
- Apr 23, 2029
- Fully finished
- Apr 24, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with adverse events (AEs)
Measured over: Up to approximately 2 years
Number of participants with serious adverse events (SAEs)
Measured over: Up to approximately 2 years
Number of participants with AEs meeting dose-limiting toxicity (DLT) criteria
Measured over: Up to 21 days
Number of participants with AEs leading to discontinuation
Measured over: Up to approximately 2 years
Number of participants with AEs leading to death
Measured over: Up to approximately 2 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07325136 · record last updated 2026-09-14 · checked 2026-11-09 15:42 UTC